20 articles
Fisetin is emerging as a top senolytic candidate, clearing senescent cells linked to aging — and strawberries are its richest dietary source.
Researchers identified polyunsaturated fatty acids that may help eliminate senescent cells linked to aging and disease.
Rubedo's RLS-1496 reduced actinic keratosis lesions by 46% in four weeks with minimal side effects, targeting aging cells behind the damage.
A UC San Diego trial shows ION224 blocks liver fat production, cutting inflammation and scarring in 60% of MASH patients.
Mountain View biotech's RLS-1496 becomes first GPX4-targeting senolytic to enter human trials, using AI platform to eliminate aging cells.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
ProJenX completes enrollment for Prosetin's Phase 1b ALS trial, reporting strong safety data and target engagement at therapeutic doses.
A major RCT shows finerenone reduces kidney function loss by 23% in non-diabetic CKD patients, expanding its protective role beyond diabetes.
Sironax's SARM1 inhibitor SIR2501 wins FDA Fast Track status for chemotherapy-induced nerve damage, with trials also targeting ALS.
Rubedo's RLS-1496 demonstrates early clinical signals in removing senescent cells through GPX4 modulation in human skin tissue.
A topical senolytic drug cleared aging 'zombie' cells from old skin, helping aged mice heal wounds 43% more completely by day 24.
Dasatinib and quercetin, a leading senolytic combo, unexpectedly reduced myelination in healthy mouse brains, mimicking multiple sclerosis damage.
Diranersen reduced tau biomarkers and slowed cognitive decline in early Alzheimer's patients, marking a milestone for tau-directed therapy.
OrsoBio's mitochondrial drug TLC-6740 added 4.5% more weight loss on top of tirzepatide in a Phase 2a trial, with bonus metabolic and cognitive benefits.
A Phase 2 trial of Nivisnebart for early Alzheimer's is stopped after independent reviewers found it unlikely to slow disease progression.
FORZINITY becomes the first FDA-approved therapy targeting mitochondria directly, launching for Barth syndrome patients amid a company rebrand.
OrsoBio's oral TLC-6740 paired with tirzepatide boosted weight loss by an extra 4.5% in 24 weeks, with gains in insulin sensitivity and liver health.
Phase II trial shows petrelintide, a weekly amylin injectable, achieves meaningful weight loss with far fewer nausea and vomiting events than GLP-1 drugs.
Topical therapy RLS-1496 met primary endpoints in Phase 1 trial with no serious adverse events in psoriasis patients.
Metashape Pharma's MS 001 paired with semaglutide shows fat-selective weight loss and muscle preservation in preclinical mouse studies.
